Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
14 Jan 2022
14 Jan 2022
Historique:
received:
30
11
2020
accepted:
02
12
2021
entrez:
14
1
2022
pubmed:
15
1
2022
medline:
16
2
2022
Statut:
ppublish
Résumé
Real-world evidence on a potential statin effect modification by sex is inconclusive, especially for the primary prevention of cardiovascular disease (CVD). We aimed to quantify the differences in the effect of statins on lipid parameters between men and women.The PharmLines Initiative linked the Lifelines Cohort Study and the IADB.nl prescription database. This database covers a representative population from the Netherlands. We selected participants aged ≥40 years at the index date: the date of the first prescription of any statin monotherapy in the study period 2006 to 2017. Multivariate regression modeling was used to compare the difference of the mean percentage change of lipid parameters (% mean difference [MD]) from baseline to follow-up measurement between the sexes.Out of 5366 statin users from approximately 50,000 participants available in the final linked database, 685 were statin initiators. At baseline, women had significantly higher levels of mean total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) than men (all P values <.01). At follow-up, women had a significantly higher mean percentage change of HDL-C compared to men (adjusted % MD 5.59, 95% confidence interval [CI] 2.42-8.75, P < .01). There was no significant sex difference in other parameters, nor in the proportion of men and women who achieved LDL-C ≤2.5 mmol/L.Statins appear to have a greater effect on increasing HDL-C levels in women than men while showing similar effect on other lipid parameters in both sexes. Men should not be treated differently than women.
Identifiants
pubmed: 35029178
doi: 10.1097/MD.0000000000028394
pii: 00005792-202201140-00008
pmc: PMC8758030
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28394Subventions
Organisme : University Medical Center Groningen and the University of Groningen; Indonesia Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan, LPDP)
ID : Not applicable
Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res 2017;121:677–94.
Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37:3232–45.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016;37:2315–81.
Nederlands Huisartsen Genootschap. Multidisciplinaire richtlijn Cardiovasculair risicomanagement, herziening 2011. Utrecht: Nederlands Huisartsen Genootschap; 2011.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1046–81.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999–3058.
American Heart Association/American College of Cardiology. 2018 Prevention guidelines tool CV risk calculator. Published 2018. Available at: http://static.heart.org/riskcalc/app/index.html#!/baseline-risk . Accessed October 10, 2019.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397–405.
Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012;59:572–82.
Cangemi R, Romiti GF, Campolongo G, et al. Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: the never-ending debate. Pharmacol Res 2017;117:148–55.
Karlson BW, Palmer MK, Nicholls SJ, Barter PJ, Lundman P. Effects of age, gender and statin dose on lipid levels: results from the VOYAGER meta-analysis database. Atherosclerosis 2017;265:54–9.
Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197doi:10.1136/bmj.c2197.
doi: 10.1136/bmj.c2197
Hyun KK, Redfern J, Patel A, et al. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare. Heart 2017;103:492–8.
Lewey J, Shrank WH, Bowry ADK, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 2013;165:665–78.e1.
Zhang H, Plutzky J, Shubina M, Turchin A. Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study. PLoS One 2016;11:e0155228doi:10.1371/journal.pone.0155228.
doi: 10.1371/journal.pone.0155228
Karp I, Chen S-F, Pilote L. Sex differences in the effectiveness of statins after myocardial infarction. CMAJ 2007;176:333–8.
Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532doi:10.1136/bmj.k3532.
doi: 10.1136/bmj.k3532
van der Ende MY, Hartman MHT, Hagemeijer Y, et al. The LifeLines Cohort Study: prevalence and treatment of cardiovascular disease and risk factors. Int J Cardiol 2017;228:495–500.
Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma M. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res 2013;13:285–92.
Scholtens S, Smidt N, Swertz MA, et al. Cohort profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 2015;44:1172–80.
Sediq R, van der Schans J, Dotinga A, et al. Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort Study with the pharmacy database IADB.nl: the PharmLines Initiative. Clin Epidemiol 2018;10:981–9.
Stolk RP, Rosmalen JGM, Postma DS, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008;23:67–74.
Wiersma T, Smulders YM, Stehouwer CD, Konings KT, Lanphen J. Samenvatting van de multidisciplinaire richtlijn ‘Cardiovasculair risicomanagement’ (herziening 2011) [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)]. Ned Tijdschr Geneeskd 2012;156:A5104.
Balder JW, de Vries JK, Nolte IM, Lansberg P, Kuivenhoven J, Kamphuisen P. Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: age- and gender-specific baseline lipid values and percentiles. J Clin Lipidol 2017;11:1055–64.e6.
Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010;4:462–71.
Hair JF Jr, Black WC, Babin BJ, Anderson RE. Multivariate Data Analysis. 7th edUpper Saddle River, NJ: Prentice Hall; 2009.
Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 2010;51:1546–53.
Davidson MH, Ose L, Frohlich J, et al. Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clin Cardiol 2003;26:509–14.
Chang Y-H, Lin K-C, Chang D-M, Hsieh C-H, Lee Y-J. Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients. Rev Diabet Stud 2013;10:213–22.
Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 2010;17:436–51.
Deshpande S, Quek RGW, Forbes CA, et al. A systematic review to assess adherence and persistence with statins. Curr Med Res Opin 2017;33:769–78.
Kuiper J, Sanchez R, Houben E, et al. Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands. Clin Ther 2017;39:819–27.e1.
Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N. Representativeness of the Lifelines Cohort Study. PLoS One 2015;10:e0137203doi:10.1371/journal.pone.0137203.
doi: 10.1371/journal.pone.0137203